Under normal circumstances, your heart beats in a steady rhythm, usually between 60 and 100 times per minute when you’re resting. This regular beat is what keeps blood flowing smoothly through your body. However, in atrial fibrillation (AFib), the rhythm is off, and the two upper chambers of the heart (the atria) can beat up to 300 times per minute in a chaotic and uncoordinated way. You can usually check this by feeling your pulse at your wrist or neck.
This irregular heart rhythm makes it difficult for the heart to pump blood effectively. When blood pools in the atria, it increases the risk of forming blood clots. If one of these clots reaches your brain, it can block blood flow and cause an ischemic stroke, which is a stroke caused by a blocked artery. According to experts, AFib is responsible for 15 to 20% of all strokes, many of which lead to heart failure, permanent disability, or death.
Alarming as it is, AFib is not often life-threatening. However, it does require treatment to manage the symptoms and reduce the risk of stroke. Common treatments include medications to prevent stroke and control the heart's rhythm or rate, as well as procedures like cardioversion and catheter ablation. Your doctor may also recommend a left atrial appendage if you can’t take a blood thinner due to the risk of bleeding or falls.
Clinical trials are also underway, testing new treatments and therapies that aim to reduce the risks of AFib, improve patient care, and make managing heart health easier and more effective.
Medications for atrial fibrillation (AFib) can help manage the condition, but they’re not without their drawbacks. While these drugs are effective, they also come with limitations and can sometimes cause side effects that are uncomfortable or even dangerous. For example, a recent study found that patients on anti-AFib medications often need more pacemakers and face more hospitalizations due to a slower heart rate. Because of these risks, doctors need to carefully weigh the benefits of these medications against their potential downsides.
Thankfully, there are other options beyond medication. One of the most promising alternatives is AFib ablation, also known as catheter ablation. This procedure creates tiny scars in specific areas of the heart to block the abnormal electrical signals that cause arrhythmia.
Studies have shown that a single ablation procedure can reduce or eliminate AFib in about 70% to 80% of patients. This makes ablation more effective than drug therapy in controlling irregular heart rhythms.
However, existing ablative therapy has limitations, too. These include potentially highly morbid complications like phrenic nerve injury and atrial fistula. According to experts, traditional approaches use thermal energy sources like laser, radiofrequency, cryo energy, etc., all of which carry an associated short-and long-term injury risk to nearby structures.
These limitations led to new technology that is even more effective and safer. Let’s explore some of the latest innovations in AFib ablation:
Pulsed Field Ablation (PFA) is a newer technique that uses short, precise bursts of electrical energy to create scar tissue in the heart. The FDA approved the first PFA system in December 2023 to treat persistent and paroxysmal atrial fibrillation. A recent review found PFA to be a promising approach to arrhythmia atrial fibrillation treatment due to its improved safety compared to thermal ablation. PFA only targets heart cells that need to be treated while leaving surrounding tissues unharmed.
A ganglionated plexi ablation is a treatment option for a specific group of AFib patients. Research shows that ganglionated plexi—clusters of nerve cells—are commonly found on the back surface of the right atrium. These nerve clusters are believed to play a key role in triggering and sustaining AFib. Targeting and ablating these nerve clusters in the left atrium provides a more personalized treatment option, especially for patients whose AFib is linked to nerve activity.
The convergent procedure is a hybrid technique that combines the strengths of catheter ablation with a minimally invasive surgical approach. This allows doctors to reach and treat areas of the heart that are difficult to access with traditional methods. It’s a more comprehensive treatment that can improve the chances of successfully managing persistent AFib.
Vein of Marshall Ablation is a minimally invasive procedure for people who experience persistent atrial fibrillation symptoms. Patients with atrial fibrillation usually start with a pulmonary vein isolation ablation to stop the irregular electrical signals that cause abnormal heart rhythms. However, if the symptoms last longer than seven days, this procedure alone may not be enough.
For those with persistent symptoms, an additional treatment called vein of Marshall Ablation with ethanol infusion can be used. When combined with pulmonary vein isolation, this procedure targets and removes extra triggers and risk factors that can cause atrial fibrillation.
Traditionally, anticoagulant therapy is used to reduce the risk of stroke in people with AFib. However, these medications can increase the risk of bleeding, which is a serious concern. New medications being tested in clinical trials for heart diseases aim to offer effective stroke prevention with fewer adverse events. These drugs could become the new standard of care if they prove safer and more effective than existing options.
Clinical trials are crucial because they help doctors and researchers learn more about what works best in real-world situations. They provide valuable insights into how new treatments can improve patient outcomes, reduce the risk of stroke, and enhance the quality of life for those living with AFib.
As innovations are tested and refined, they have the potential to change the way AFib is treated across the world. And the best part is that you can participate in this process by enrolling in a clinical trial.
The ongoing research and development in the field of atrial fibrillation treatment offer hope for better, safer, and more effective ways to manage this condition. As clinical trials continue to explore new possibilities, the advancements made today will pave the way for improved heart health tomorrow.
